Drugs / AZD0466
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05205161 | Jul 2022 → Aug 2023 | non-Hodgkin lymphoma | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT04865419 | Jun 2021 → Aug 2023 | hematopoietic and lymphoid cell neoplasm | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT04214093 | Dec 2019 → Jun 2021 | plasma cell myeloma | AstraZeneca | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2023-07-31 | Starpharma Pty Ltd | Results Partnered Program Update starpharma.com ↗
These AEs have been observed in the two clinical trials evaluating AZD0466 in haematological indications (NCT04865419 and NCT05205161). |
| 2023-06-26 | Starpharma Pty Ltd | Regulatory Clinical Trial Update starpharma.com ↗
A voluntary partial clinical hold has been implemented on a trial in which Starpharma (ASX: SPL, OTCQX: SPHRY) technology is used: AZD0466 Monotherapy or in Combination in Patients w ith Advanced Haematological Malignancies (NCT04865419). |
| 2023-06-23 | Starpharma Pty Ltd | Results Life Sciences Investor Forum Presentation starpharma.com ↗
AZD0466 was active in 50% of SCLC models, resulting in tumour regression in 33% of models. |
| 2023-06-14 | Starpharma Pty Ltd | Results AZD0466 Clinical Data Presented by AstraZeneca EHA Congress starpharma.com ↗
AZD0466 continues to be well tolerated in patients with relapsed/refractory acute leukaemia, with adverse events matching expected toxicity based on data from preclinical studies, and evidence of Bcl/xL on-target anti-leukaemia clinical activity i n line with preclinical models . |
| 2023-05-16 | AstraZeneca | Results AstraZeneca showcases scientific advances across rare and malignant haematological conditions at EHA 2023 astrazeneca.com ↗
Preliminary ongoing Phase I/II safety and tolerability results of AZD0466, a Bcl-2/Bcl-xl inhibitor, will show it is tolerated as a monotherapy for patients with relapsed or refractory acute leukaemia. |
| 2023-04-19 | Starpharma Pty Ltd | Results AZD0466 active in small cell lung cancer patient models starpharma.com ↗
AZD0466 was active in 50% of SCLC models, resulting in tumour regression in 33% of models. |
| 2022-12-13 | Starpharma Pty Ltd | Results Positive AZD0466 clinical data presented by AstraZeneca starpharma.com ↗
The clinical data reported show that AZD0466 has been well tolerated, with no DLTs reported to date and no discontinuations due to treatment -related adverse events. |
| 2022-11-30 | AstraZeneca | Results AstraZeneca showcases strength of haematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022 astrazeneca.com ↗
Preliminary results from an ongoing Phase I trial will demonstrate that Bcl-2/Bcl-xl inhibitor AZD0466 has been well-tolerated in patients with advanced haematologic malignancies. |
| 2020-06-22 | Starpharma Pty Ltd | Results DEP products showcased at AACR 2020 starpharma.com ↗
The AZD0466 posters highlight the significant improvement in therapeutic index delivered by the DEP® technology, enabling the progression of AZD0466 into the clinic. |
| 2019-09-25 | Starpharma Pty Ltd | Regulatory FDA Authorises Clinical Trial with AstraZeneca DEP product starpharma.com ↗
today announced that that the U.S. Food and Drug Administration (FDA) has authorised the use of AstraZeneca’s DEP® Bcl2/xL conjugate AZD0466 in clinical trials under an investigational new drug (IND) application. |
All press releases naming this drug 13 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0466 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05205161 ↗ |
| Route | Intravenous | “administered IV” NCT04214093 ↗ |